The CAR-T field is increasingly shifting toward in vivo approaches, according to industry reporting that points to growing momentum behind therapies that aim to generate CAR-T cells inside the patient rather than manufacturing them ex vivo. The push is supported by big pharma acquisition activity and clinical pipeline moves hitting the clinic. For developers, in vivo CAR-T programs are designed to streamline logistics and potentially improve access, but they also raise new translational and safety considerations around control of gene delivery, expression, and duration of activity. The recent activity highlights that large oncology strategists view this modality as a next platform layer, not just a niche academic direction. In practical terms, companies evaluating in vivo CAR-T are likely to face scrutiny on dosing, biodistribution, and on-target/off-tumor risk as regulators and payers focus on real-world manageability as well as clinical efficacy.